BioSpace News Archive

SEMINAL PRESENTATION OF FIRST ANALYTICAL VALIDATION DATA SCHEDULED FOR JUNE 30.

New branding unifies Numinus’ presence across North America.

Eliem Therapeutics, Inc., today announced that it has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP), a condition commonly referred to as sciatica.

Centogene N.V., the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, announced the appointment of Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22, 2022.

Precigen, Inc. (Nasdaq: PGEN), today announced that Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual panel discussion titled, “Targeted T Cell Therapies, Including Autologous CAR T, TCR and More” on Thursday, June 30, 2022, at 1:00 PM ET at the Stifel 2022 Virtual Cell Therapy Summit.

Provides updates across 2030 Corporate Responsibility Commitment and Goals.

New nVision ™ Platform enables neuroscience researchers to synchronously acquire behavioral videos with in vivo miniscope images.

Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder.

Artelo Biosciences, Inc. announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results entitled, “Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12.

Dr. Moore will lead Zymeworks’ Early Research & Development Group responsible for advancing the Company’s next-generation of multispecific antibody programs and antibody drug conjugate (ADC) programs into clinical studies.